Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Comparisons of Gastric Cancer Treatments: East vs. West

  • Bickenbach, Kai (Department of Surgery, University of Medicine and Dentistry of New Jersey-New Jersey Medical School) ;
  • Strong, Vivian E (Department of Surgery, Memorial Sloan-Kettering Cancer Center)
  • Received : 2012.06.08
  • Accepted : 2012.06.11
  • Published : 2012.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

There has been a large amount of speculation concerning the differences in the outcomes in patients who have gastric cancer in the Eastern and Western worlds. The differences in biology, surgical and adjuvant treatment have been used to explain such differences. There are clear differences observed in the histology (diffuse vs. intestinal), tumor location (proximal vs. distal), environmental exposures, dietary factors and Helicobacter pylori status. A higher incidence of gastric cancer in the East has led to screening programs, and leading to an earlier stage at presentation. Surgical treatment differs in that the extended lymph node dissection is routinely practiced in the Asian countries. Additionally, different adjuvant therapeutic regimens are used in both regions. The purpose of this review is to describe the differences in both presentation and treatment between the East and the West.

Keywords

References

  1. Steigman SA, Kunisaki SM, Wilkins-Haug L, Takoudes TC, Fauza DO. Optical properties of human amniotic fluid: implications for videofetoscopic surgery. Fetal Diagn Ther 2010;27:87-90. https://doi.org/10.1159/000262279
  2. Kunisaki C, Makino H, Kimura J, Takagawa R, Kosaka T, Ono HA, et al. Impact of lymphovascular invasion in patients with stage I gastric cancer. Surgery 2010;147:204-211. https://doi.org/10.1016/j.surg.2009.08.012
  3. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011;29:4387-4393. https://doi.org/10.1200/JCO.2011.36.5908
  4. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820. https://doi.org/10.1056/NEJMoa072252
  5. Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y, et al; Gastric Cancer Surgical Study Group, Japan Clinical Oncology Group. Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosanegative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol 2003;21:2282-2287. https://doi.org/10.1200/JCO.2003.06.103
  6. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730 https://doi.org/10.1056/NEJMoa010187
  7. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20. https://doi.org/10.1056/NEJMoa055531
  8. Hanazaki K, Sodeyama H, Wakabayashi M, Miyazawa M, Yokoyama S, Sode Y, et al. Surgical treatment of gastric cancer detected by mass screening. Hepatogastroenterology 1997;44:1126-1132.
  9. Schlemper RJ, Itabashi M, Kato Y, Lewin KJ, Riddell RH, Shimoda T, et al. Differences in diagnostic criteria for gastric carcinoma between Japanese and western pathologists. Lancet 1997;349:1725-1729. https://doi.org/10.1016/S0140-6736(96)12249-2
  10. Theuer CP. Asian gastric cancer patients at a southern California comprehensive cancer center are diagnosed with less advanced disease and have superior stage-stratified survival. Am Surg 2000;66:821-826.
  11. Theuer CP, Kurosaki T, Ziogas A, Butler J, Anton-Culver H. Asian patients with gastric carcinoma in the United States exhibit unique clinical features and superior overall and cancer specific survival rates. Cancer 2000;89:1883-1892. https://doi.org/10.1002/1097-0142(20001101)89:9<1883::AID-CNCR3>3.3.CO;2-8
  12. Strong VE, Song KY, Park CH, Jacks LM, Gonen M, Shah M, et al. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg 2010;251:640-646. https://doi.org/10.1097/SLA.0b013e3181d3d29b
  13. Noguchi Y, Yoshikawa T, Tsuburaya A, Motohashi H, Karpeh MS, Brennan MF. Is gastric carcinoma different between Japan and the United States? Cancer 2000;89:2237-2246. https://doi.org/10.1002/1097-0142(20001201)89:11<2237::AID-CNCR12>3.0.CO;2-9
  14. Willis J, Riddell RH. Biology versus terminology: East meets West in surgical pathology. Gastrointest Endosc 2003;57:369- https://doi.org/10.1067/mge.2003.106
  15. Lauwers GY, Shimizu M, Correa P, Riddell RH, Kato Y, Lewin KJ, et al. Evaluation of gastric biopsies for neoplasia: differences between Japanese and Western pathologists. Am J Surg Pathol 1999;23:511-518. https://doi.org/10.1097/00000478-199905000-00003
  16. Schwarz RE, Zagala-Nevarez K. Ethnic survival differences after gastrectomy for gastric cancer are better explained by factors specific for disease location and individual patient comorbidity. Eur J Surg Oncol 2002;28:214-219. https://doi.org/10.1053/ejso.2001.1234
  17. Yao JC, Schnirer II, Reddy S, Chiang S, Najam A, Yu C, et al. Effects of sex and racial/ethnic group on the pattern of gastric cancer localization. Gastric Cancer 2002;5:208-212. https://doi.org/10.1007/s101200200036
  18. Verdecchia A, Mariotto A, Gatta G, Bustamante-Teixeira MT, Ajiki W. Comparison of stomach cancer incidence and survival in four continents. Eur J Cancer 2003;39:1603-1609. https://doi.org/10.1016/S0959-8049(03)00360-5
  19. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-1289. https://doi.org/10.1001/jama.1991.03460100089030
  20. Hansson LE, Sparén P, Nyrén O. Increasing incidence of carcinoma of the gastric cardia in Sweden from 1970 to 1985. Br J Surg 1993;80:374-377. https://doi.org/10.1002/bjs.1800800338
  21. Kattan MW, Karpeh MS, Mazumdar M, Brennan MF. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol 2003;21:3647-3650. https://doi.org/10.1200/JCO.2003.01.240
  22. Kunisaki C, Makino H, Takagawa R, Sato K, Kawamata M, Kanazawa A, et al. Predictive factors for surgical complications of laparoscopy-assisted distal gastrectomy for gastric cancer. Surg Endosc 2009;23:2085-2093. https://doi.org/10.1007/s00464-008-0247-8
  23. Chern H, Chou J, Donkor C, Shia J, Guillem JG, Nash GM, et al. Effects of obesity in rectal cancer surgery. J Am Coll Surg 2010;211:55-60. https://doi.org/10.1016/j.jamcollsurg.2010.03.010
  24. Hirasawa T, Gotoda T, Miyata S, Kato Y, Shimoda T, Taniguchi H, et al. Incidence of lymph node metastasis and the feasibility of endoscopic resection for undifferentiated-type early gastric cancer. Gastric Cancer 2009;12:148-152. https://doi.org/10.1007/s10120-009-0515-x
  25. Uedo N, Iishi H, Tatsuta M, Ishihara R, Higashino K, Takeuchi Y, et al. Longterm outcomes after endoscopic mucosal resection for early gastric cancer. Gastric Cancer 2006;9:88-92. https://doi.org/10.1007/s10120-005-0357-0
  26. Kim JJ, Lee JH, Jung HY, Lee GH, Cho JY, Ryu CB, et al. EMR for early gastric cancer in Korea: a multicenter retrospective study. Gastrointest Endosc 2007;66:693-700. https://doi.org/10.1016/j.gie.2007.04.013
  27. Soetikno R, Kaltenbach T, Yeh R, Gotoda T. Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract. J Clin Oncol 2005;23:4490-4498. https://doi.org/10.1200/JCO.2005.19.935
  28. Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 1996;347:995-999. https://doi.org/10.1016/S0140-6736(96)90144-0
  29. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999;79:1522-1530. https://doi.org/10.1038/sj.bjc.6690243
  30. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ, Welvaart K, Songun I, et al; Dutch Gastric Cancer Group. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999;340:908-914. https://doi.org/10.1056/NEJM199903253401202
  31. Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004;22:2069-2077. https://doi.org/10.1200/JCO.2004.08.026
  32. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010;11:439-449. https://doi.org/10.1016/S1470-2045(10)70070-X
  33. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al; Japan Clinical Oncology Group. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008;359:453-462. https://doi.org/10.1056/NEJMoa0707035
  34. Redaniel MT, Laudico A, Mirasol-Lumague MR, Gondos A, Pulte D, Mapua C, et al. Cancer survival discrepancies in developed and developing countries: comparisons between the Philippines and the United States. Br J Cancer 2009;100:858- https://doi.org/10.1038/sj.bjc.6604945
  35. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 2006;7:309-315. https://doi.org/10.1016/S1470-2045(06)70623-4
  36. Sala FG, Kunisaki SM, Ochoa ER, Vacanti J, Grikscheit TC. Tissue-engineered small intestine and stomach form from autologous tissue in a preclinical large animal model. J Surg Res 2009;156:205-212. https://doi.org/10.1016/j.jss.2009.03.062
  37. Nakajima T, Kinoshita T, Nashimoto A, Sairenji M, Yamaguchi T, Sakamoto J, et al; National Surgical Adjuvant Study of Gastric Cancer Group. Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg 2007;94:1468-1476. https://doi.org/10.1002/bjs.5996
  38. Kinoshita T, Nakajima T, Ohashi Y. Adjuvant chemotherapy with uracil-tegafur (UFT) for serosa negative advanced gastric cancer: results of a randomized trial by national surgical adjuvant study of gastric cancer. Prog Proc Am Soc Clin Oncol 2005;23:313s-313s.
  39. Gill S, Shah A, Le N, Cook EF, Yoshida EM. Asian ethnicityrelated differences in gastric cancer presentation and outcome among patients treated at a canadian cancer center. J Clin Oncol 2003;21:2070-2076. https://doi.org/10.1200/JCO.2003.11.054
  40. Bollschweiler E, Boettcher K, Hoelscher AH, Sasako M, Kinoshita T, Maruyama K, et al. Is the prognosis for Japanese and German patients with gastric cancer really different? Cancer 1993;71:2918-2925. https://doi.org/10.1002/1097-0142(19930515)71:10<2918::AID-CNCR2820711006>3.0.CO;2-V

Cited by

  1. Radiotherapy for tumors of the stomach and gastroesophageal junction – a review of its role in multimodal therapy vol.7, pp.1, 2012, https://doi.org/10.1186/1748-717x-7-192
  2. Gastric cancer-molecular and clinical dimensions vol.10, pp.11, 2012, https://doi.org/10.1038/nrclinonc.2013.170
  3. Advanced gastric cancer: is chemotherapy needed after surgery? vol.7, pp.8, 2012, https://doi.org/10.1586/17474124.2013.841542
  4. Adjuvant Treatment for Gastric Cancer: Chemotherapy Versus Radiation vol.18, pp.9, 2013, https://doi.org/10.1634/theoncologist.2012-0462
  5. Measuring patient-reported outcomes in advanced gastric cancer vol.7, pp.None, 2013, https://doi.org/10.3332/ecancer.2013.351
  6. Endoluminal surgical triangulation: overcoming challenges of colonic endoscopic submucosal dissections using a novel flexible endoscopic surgical platform: feasibility study in a porcine model vol.27, pp.11, 2013, https://doi.org/10.1007/s00464-013-3049-6
  7. BMI and lymph node ratio may predict clinical outcomes of gastric cancer vol.10, pp.2, 2012, https://doi.org/10.2217/fon.13.188
  8. Complications Following Surgery for Gastric Cancer: Analysis of Prospectively Collected Data vol.5, pp.14, 2012, https://doi.org/10.4236/jct.2014.514147
  9. Improving the outcomes in gastric cancer surgery vol.20, pp.38, 2012, https://doi.org/10.3748/wjg.v20.i38.13692
  10. Laparoscopic robotic total gastrectomy vol.9, pp.4, 2014, https://doi.org/10.5114/wiitm.2014.45128
  11. Ramucirumab: Successfully Targeting Angiogenesis in Gastric Cancer vol.20, pp.23, 2012, https://doi.org/10.1158/1078-0432.ccr-14-1071
  12. Comparison of the 6th and 7th editions of the AJCC/UICC TNM staging system for gastric cancer focusing on the “N” parameter-related survival: the monoinstitutional NodUs Italian study vol.13, pp.None, 2012, https://doi.org/10.1186/s12957-015-0633-3
  13. Locally Advanced Gastroesophageal Junction Tumor: A Treatment Dilemma vol.20, pp.2, 2015, https://doi.org/10.1634/theoncologist.2014-0377
  14. Significant Differences in the Clinicopathological Characteristics and Survival of Gastric Cancer Patients from Two Cancer Centers in China and Korea vol.15, pp.1, 2012, https://doi.org/10.5230/jgc.2015.15.1.19
  15. Treating operable patients with gastric cancer: Macdonald's protocol versus adjuvant chemotherapy vol.11, pp.16, 2012, https://doi.org/10.2217/fon.15.141
  16. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors vol.33, pp.28, 2012, https://doi.org/10.1200/jco.2014.58.3930
  17. Clinical characteristics of hepatoduodenal lymph node metastasis in gastric cancer vol.21, pp.38, 2012, https://doi.org/10.3748/wjg.v21.i38.10866
  18. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas vol.64, pp.11, 2012, https://doi.org/10.1136/gutjnl-2014-308252
  19. Health state utility values associated with advanced gastric, oesophageal, or gastro-oesophageal junction adenocarcinoma: a systematic review vol.18, pp.11, 2012, https://doi.org/10.3111/13696998.2015.1066380
  20. Role of robot-assisted distal gastrectomy compared to laparoscopy-assisted distal gastrectomy in suprapancreatic nodal dissection for gastric cancer vol.30, pp.4, 2016, https://doi.org/10.1007/s00464-015-4372-x
  21. Genomic alterations and molecular subtypes of gastric cancers in Asians vol.35, pp.1, 2012, https://doi.org/10.1186/s40880-016-0106-2
  22. Gastric cancer: Current status of lymph node dissection vol.22, pp.10, 2016, https://doi.org/10.3748/wjg.v22.i10.2875
  23. Efficacy and toxicity of salvage weekly paclitaxel chemotherapy in non-Asian patients with advanced oesophagogastric adenocarcinoma vol.8, pp.2, 2012, https://doi.org/10.1177/1758834015621669
  24. Subtotal gastrectomy with conventional D2 lymphadenectomy for carcinoma of the distal gastric portion: A retrospective cohort study on clinical outcomes ☆ vol.6, pp.None, 2016, https://doi.org/10.1016/j.amsu.2016.01.023
  25. Current advances in targeted therapies for metastatic gastric cancer: improving patient care vol.12, pp.6, 2016, https://doi.org/10.2217/fon.15.348
  26. MiR-148a Functions as a Tumor Suppressor by Targeting CCK-BR via Inactivating STAT3 and Akt in Human Gastric Cancer vol.11, pp.8, 2016, https://doi.org/10.1371/journal.pone.0158961
  27. Bioengineering the gut: future prospects of regenerative medicine vol.13, pp.9, 2012, https://doi.org/10.1038/nrgastro.2016.124
  28. Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy vol.21, pp.10, 2016, https://doi.org/10.4103/1735-1995.192504
  29. Examining the gastric cancer survival gap between Asians and whites in the United States vol.20, pp.4, 2012, https://doi.org/10.1007/s10120-016-0667-4
  30. Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors vol.56, pp.1, 2012, https://doi.org/10.1007/s40262-016-0427-y
  31. Adjuvant Chemoradiotherapy for Non-Pretreated Gastric Cancer vol.24, pp.12, 2017, https://doi.org/10.1245/s10434-017-6048-3
  32. Evaluation of prognostic value and stage migration effect using positive lymph node ratio in gastric cancer vol.43, pp.1, 2012, https://doi.org/10.1016/j.ejso.2016.08.002
  33. East Versus West vol.97, pp.2, 2012, https://doi.org/10.1016/j.suc.2016.12.002
  34. Somatic copy number alterations in gastric adenocarcinomas among Asian and Western patients vol.12, pp.4, 2012, https://doi.org/10.1371/journal.pone.0176045
  35. Up-regulation of CRKL by microRNA-335 methylation is associated with poor prognosis in gastric cancer vol.17, pp.None, 2012, https://doi.org/10.1186/s12935-017-0387-9
  36. Evolution in the surgical management of gastric cancer: is extended lymph node dissection back in vogue in the USA? vol.15, pp.None, 2012, https://doi.org/10.1186/s12957-017-1204-6
  37. MicroRNA-154 Inhibits the Growth and Invasion of Gastric Cancer Cells by Targeting DIXDC1/WNT Signaling vol.26, pp.6, 2012, https://doi.org/10.3727/096504017x15016337254632
  38. Multimodality treatment of operable gastric and oesophageal adenocarcinoma: evaluating neoadjuvant, adjuvant and perioperative approaches vol.18, pp.4, 2012, https://doi.org/10.1080/14737140.2018.1438271
  39. A review of capecitabine-based adjuvant therapy for gastric cancer in the Chinese population vol.14, pp.8, 2012, https://doi.org/10.2217/fon-2017-0558
  40. Surgicopathological Quality Control and Protocol Adherence to Lymphadenectomy in the CRITICS Gastric Cancer Trial vol.268, pp.6, 2012, https://doi.org/10.1097/sla.0000000000002444
  41. Assessment of the 8th edition of TNM staging system for gastric cancer: the results from the SEER and a single-institution database vol.14, pp.29, 2012, https://doi.org/10.2217/fon-2018-0299
  42. The role of surgical resection before palliative chemotherapy in advanced gastric cancer vol.9, pp.None, 2012, https://doi.org/10.1038/s41598-019-39432-7
  43. PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer vol.9, pp.None, 2012, https://doi.org/10.1038/s41598-019-41177-2
  44. THERAPEUTIC TREATMENT OF STOMACH CANCER vol.2019, pp.1, 2012, https://doi.org/10.29254/2077-4214-2019-1-1-148-70-75
  45. miR-203 Inhibits the Invasion and EMT of Gastric Cancer Cells by Directly Targeting Annexin A4 vol.27, pp.7, 2019, https://doi.org/10.3727/096504018x15444387696532
  46. LncRNA SNHG20 contributes to cell proliferation and invasion by upregulating ZFX expression sponging miR‐495‐3p in gastric cancer vol.120, pp.3, 2012, https://doi.org/10.1002/jcb.27539
  47. Clinical Evaluation of CA72-4 for Screening Gastric Cancer in a Healthy Population: A Multicenter Retrospective Study vol.11, pp.5, 2019, https://doi.org/10.3390/cancers11050733
  48. Association Between Compliance to an Enhanced Recovery Protocol and Outcome After Elective Surgery for Gastric Cancer. Results from a Western Population-Based Prospective Multicenter Study vol.43, pp.10, 2012, https://doi.org/10.1007/s00268-019-05068-x
  49. Recurrence after preoperative chemotherapy and surgery for gastric adenocarcinoma: a multicenter study vol.22, pp.6, 2012, https://doi.org/10.1007/s10120-019-00956-6
  50. Prognostic implications of the eighth edition of the union for international cancer control – classification for gastric cancer patients from specialized treatment centers in Germany and Korea vol.99, pp.6, 2020, https://doi.org/10.1097/md.0000000000018922
  51. Validation of the ACS NSQIP Surgical Risk Calculator for Patients with Early Gastric Cancer Treated with Laparoscopic Gastrectomy vol.20, pp.3, 2012, https://doi.org/10.5230/jgc.2020.20.e27
  52. Incidence and Grading of Complications After Gastrectomy for Cancer Using the GASTRODATA Registry : A European Retrospective Observational Study vol.272, pp.5, 2012, https://doi.org/10.1097/sla.0000000000004341
  53. A comparative whole genome analysis of Helicobacter pylori from a human dense South Asian setting vol.26, pp.1, 2012, https://doi.org/10.1111/hel.12766
  54. Isoforms of the p53 Family and Gastric Cancer: A Ménage à Trois for an Unfinished Affair vol.13, pp.4, 2021, https://doi.org/10.3390/cancers13040916
  55. Tumor characteristics and clinical outcome of peritoneal metastasis of gastric origin treated with a hyperthermic intraperitoneal chemotherapy procedure in the PERISCOPE I trial vol.123, pp.4, 2012, https://doi.org/10.1002/jso.26366
  56. ASO Author Reflections: D2 Lymphadenectomy Must be Complied No Matter the Arterial Variation vol.28, pp.5, 2012, https://doi.org/10.1245/s10434-020-09381-x
  57. Factors related to compliance with adjuvant chemotherapy in patients with gastric cancer: A retrospective single-center study vol.17, pp.1, 2021, https://doi.org/10.14216/kjco.21005
  58. Quantifying early gastric cancer in Australia: What is the opportunity for gastric endoscopic submucosal dissection? vol.36, pp.10, 2021, https://doi.org/10.1111/jgh.15552
  59. The endemic Helicobacter pylori population in Southern Vietnam has both South East Asian and European origins vol.13, pp.1, 2021, https://doi.org/10.1186/s13099-021-00452-2
  60. Textbook Outcome and Survival in Patients With Gastric Cancer : An Analysis of the Population Registry of Esophageal and Stomach Tumours in Ontario (PRESTO) vol.275, pp.1, 2012, https://doi.org/10.1097/sla.0000000000003849